V
VLST Corporation
VLStcorp.com | Insolvency, loans and more finance related information.
About VLST Corporation
VLST Corporation was a biotechnology firm established in Seattle, Washington, in May 2004 by co-founders Craig Smith and Steve Wiley. The company initiated operations as part of the Accelerator Corporation, a local incubator supporting emerging biotech companies. VLST's core mission was to research how viruses survive to identify therapeutic targets for autoimmune and inflammatory diseases like lupus and inflammatory bowel disease.
The company's business model centered on the development of monoclonal antibodies to treat conditions such as multiple sclerosis, lupus, psoriasis, and rheumatoid arthritis. In its early stages, VLST identified over 70 potential therapeutic targets, with eight being novel discoveries at the time. The firm successfully secured approximately $4 million in an initial funding round. A significant milestone was achieved in June 2006 when VLST raised $55 million in a Series B funding round from a consortium of nine investors, including TPG, Versant Ventures, Arch Venture Partners, and Amgen, bringing its total funding to $59.8 million.
In January 2006, Martin A. Simonetti, previously the CFO of Dendreon Corp., was appointed as President and Chief Executive Officer. Simultaneously, biotech industry veteran Steven Gillis, a co-founder of Immunex and Corixa, joined as the executive chairman of the board. Simonetti's background included various roles at Amgen Inc. and Genentech Inc., providing him with extensive experience in the biotech sector. Following the second funding round, VLST planned to graduate from the Accelerator incubator and establish its own office and research facilities. According to company filings, VLST Corporation is now considered a deadpooled company.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Employees
- 8
- Open positions
- None listed
- Industry
- Health, Fintech
- Sub-industry
- Mortgages & Lending, Wealth Management
- Sector
- Trading, Testing, Verification, Risk Management, Lead Generation, Biotechnology, Oncology, Appliances
- Business model
- Marketplace & ecommerce
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2006 | $55M | $220M | OVP Venture Partners · ARCH Venture Partners · Amgen Ventures · MPM BioImpact | — |
Growth signals
Latest recorded traffic for VLST Corporation is 0 monthly website visits. VLST Corporation's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
VLST Corporation in the Seattle ecosystem
The VLST Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- OPOVP Venture Partners
ARCH Venture Partners
Amgen Ventures
MPM BioImpact
MedImmune Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about VLST Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VLST Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










